key: cord-0843096-kt0341u3 authors: Creput, Caroline; Fumeron, Christine; Toledano, Daniel; Diaconita, Mirela; Izzedine, Hassan title: COVID-19 in Patients Undergoing Hemodialysis: Prevalence and Asymptomatic Screening During a Period of High Community Prevalence in a Large Paris Center date: 2020-10-22 journal: Kidney Med DOI: 10.1016/j.xkme.2020.09.001 sha: 2485efbaa827452dea7b923d01a9395fdf3a2519 doc_id: 843096 cord_uid: kt0341u3 RATIONALE & OBJECTIVE: Due to extensive comorbid conditions, COVID-19 has a poor prognosis in people receiving maintenance hemodialysis. In this paper, we describe our experience with 200 maintenance hemodialysis patients in a hemodialysis center that employed universal RT-PCR testing, including 38 COVID-positive patients. STUDY DESIGN: Descriptive observational cohort, including the timeline of patient diagnoses along with contextual events including precautions, testing, screening algorithms, clinical diagnostics and therapy, as well as the clinical course of the COVID infected patients and their final outcomes. SETTING & PARTICIPANTS: 200 patients within a single hemodialysis center with two dialysis clinics in Paris. RESULTS: Among 200 maintenance hemodialysis patients, 38 (19%) were diagnosed with COVID-19; of these, 15 (39.5%) were admitted to the hospital including four who required intensive care unit (ICU) care. There were 8 deaths (21%). The most common symptom was fever, followed by dry cough, fatigue and dyspnea. All COVID-19 patients had lymphopenia and an increase of C-reactive protein. The median time from the onset of respiratory symptoms to ICU admission was one to two days. The duration of non-ICU hospitalization and of ICU stays was 7 and 13 days, respectively. LIMITATIONS: Retrospective study, single HD center CONCLUSIONS: Dialysis patients are a highly susceptible population and hemodialysis centers are a high-risk area in a COVID-19 epidemic. "Unexplained" lymphopenia and/or a rise in C-reactive protein should lead physicians to the diagnosis of COVID-19, and should, when possible, be followed by diagnostic testing with universal RT-PCR as well as the reinforcement of contamination barrier measures. Conclusions: Dialysis patients are a highly susceptible population and hemodialysis centers are a high-risk area in a COVID-19 epidemic. "Unexplained" lymphopenia and/or a rise in C-reactive protein should lead physicians to the diagnosis of COVID-19, and should, when possible, be followed by diagnostic testing with universal RT-PCR as well as the reinforcement of contamination barrier measures. COVID-19 is a disease caused by a novel coronavirus. We report the first Parisian cluster of COVID-19 infection in a hemodialysis center. The prognosis of COVID-positive patients treated by maintenance hemodialysis is particularly poor, with a mortality rate of 21%. To stem this local epidemic we adopted strict isolation measures and physical distancing measures were implemented, with some difficulties. We also conducted universal testing that allowed us to identify asymptomatic patients who could be isolated in order to limit the spread of the virus. The 2019 novel coronavirus (SARS-CoV-2) epidemic was first reported in December 2019 in Wuhan, China, and has been declared a public health emergency of international concern by the World Health Organization. It may progress to a pandemic associated with substantial morbidity and mortality. 1 In the WHO European Region COVID-19 screening was implemented on January 27, 2020, linked to two clusters in Germany and France. 2 While primarily a respiratory disease, COVID-19 can cause damage to tissues and organs other than the lung leading to multi-organ dysfunction in patients at high risk. 3 Maintenance hemodialysis (HD) patients are at increased risk of COVID-19 and its complications due to a high burden of comorbid conditions and the mandatory congregate nature of hemodialysis facilities. 4 Furthermore, logistical aspects of HD may further increase the risk of disease transmission; these include frequent encounters at health care facilities with other patients and staff, the physical proximity of patients during hemodialysis, and transportation to and from hemodialysis sessions. 9 The dialysis community, recognizing the risk faced by hemodialysis patients, has published guidance and suggestions on risk mitigation of COVID-19 in this vulnerable patient population. [10] [11] [12] [13] There is limited information regarding the epidemiology of COVID-19 in maintenance HD patients. In this report, we describe our experience with COVID-19 in our center, where 38 maintenance dialysis patients developed COVID-19. J o u r n a l P r e -p r o o f This study was conducted in a center located in the 11th district of Paris. Our center includes 2 maintenance HD units (one in-center hemodialysis facility [MDU] and one self-care hemodialysis facility [AD]). All patients return home after hemodialysis sessions. Dialysis procedures, protective measures, and medical staff are similar in the two units. On March 13, 2020, we had two COVID-19 positive patients. Following recognition of these cases, we implemented barrier measures including mask wearing for all patients and caregivers, and a systematic screening procedure using a real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. Figure 1 summarizes the management flow and the outcomes of the cluster followed throughout the epidemic. Following infection identification, COVID positive patients were grouped in a confined unit. The medical team participated in discussions with the corporate clinical team of Diaverum, as well as in webinars for patients receiving hemodialysis, and created awareness posters for dialysis facilities. From March 31 to April 4, 2020, 38 moderately to severely ill or critically ill patients with confirmed COVID-19 were identified. We obtained epidemiological, clinical, laboratory, and radiological characteristics, as well as treatment and outcome data from electronic medical records for patients by using data collection forms. All data was collected in the context of care in accordance with the French law, and included the GPRD. We collected data on demographics, medical history, exposure history, underlying chronic diseases, symptoms and signs, laboratory J o u r n a l P r e -p r o o f findings, computed tomographic chest scans, and treatment (including antiviral therapy, antibiotics, corticosteroid therapy, and oxygen support). We monitored clinical data until April 15, 2020. A trained team of physicians and researchers analyzed patient medical records, independently entered, and cross-checked data in a computerized database. Real time reverse transcription polymerase chain reaction (rt-PCR) assay for SARS-Cov-2 Nasopharyngeal swab samples of patients were collected for SARS-CoV-2 test. Testing was done locally in the center by experimented nurses. The ORF1ab gene and the E gene were used for real-time rt-PCR according to the manufacturer's instructions (Roche Molecular Systems). The initial clinical laboratory investigation included a complete blood count, serum biochemical tests (including liver function, creatine kinase, lactate dehydrogenase, and electrolytes), and a coagulation profile. This was a retrospective case series study, and no patients were involved in the study design or in setting the research questions or the outcome measures directly. No patients were asked to advise on the interpretation or writing up of results. However, informed consent was given in order to collect anonymous data. J o u r n a l P r e -p r o o f On March 13, we distributed surgical masks for all nursing staff and Filtering facepiece-2 (FFP2) masks and personal protective equipment to nurses exposed to suspected or confirmed COVID patients. We limited access to the waiting room for patients, and excluded visitors from the facilities, and we triaged all patients on arrival with questions by a nurse to identify fever or respiratory symptoms. Temperature measurements and hand washing were required for all patients. We utilized separate access points for COVID patients, with separate entrances and exits. Initially, suspected or confirmed COVID patients were dialyzed in single isolation rooms, as there are six isolation rooms in the facility. When we had more than four patients, they were grouped in an extension room with five beds. When we had sixteen positive patients, they were grouped in our smaller center, which has sixteen dialysis stations. These patients attended dedicated sessions with only COVID positive patients in order to more effectively cohort those with COVID infection. Our key interventions in the context of events in France are as follows: on March 16, we distributed masks for all patients, nurses, and staff; on March 17, lockdown measures were implemented in France; on March 18, we cancelled meals during dialysis sessions; and starting on April 1, we performed nasopharyngeal testing with an RT-PCR for all nursing staff and all patients who had not previously been diagnosed with COVID-19. The total screening of our cohort took 4 days (two dialysis sessions and two different nurse teams). We did not make any changes in home medication regimens, specifically not changing existing treatment with corticosteroids or immunosuppressive drugs. For COVID patients we strictly monitored dry weight at each dialysis session with clinical methods and weekly monitoring of Brain natriuretic peptide (BNP). There were 200 patients in our HD center included in this study. The dynamic course of COVID-19 diagnosis from emergence to development is presented in Figure 2 . A total of 200 and 40 care staff were screened for COVID-19 infection. Thirtyeight patients (19%) were diagnosed with COVID-19; 36 patients tested positive with a nasopharyngeal rt-PCR for SARS-CoV2, 4 of whom were asymptomatic. The remaining 2 patients tested negative with the rt-PCR for SARS-CoV2 but had typical chest CT scan findings (bilateral ground-glass opacities). Patient characteristics are described in Table 1 . The most common symptom was fever (68%), followed by dry cough (63%), fatigue (35%), dyspnea (29%), myalgia (8%), gastrointestinal symptoms (such as diarrhea, vomiting and abdominal pain) (8%), rhinorrhea and sore throat (8%), chest pain (3%), and ageusia (3%). No patients had anosmia. All patients were on intermittent hemodialysis 3 times per week with a Polysulfone membrane and acetic acid as we stopped hemodiafiltration and citric acid at the beginning of the COVID 19 epidemic. We experienced HD system or dialyzer clotting more frequently than usual for three patients, for whom we increased the dose of heparin. We did not systematically increase the dose of heparin for all COVID positive patients. Two patients experienced arteriovenous fistulae thrombosis. We did not observe any thromboembolic events. All patients had lymphopenia <1.0 ×10⁹/L at disease onset. At the peak of the epidemic, the mean decrease of lymphocyte count was -415 ×10⁹/L (-1360 to +200 x 10⁹/L). C-reactive protein (CRP) levels increased from diagnosis until the peak of disease symptoms (mean 41 to 95 mg/L), then decreased as the symptoms disappeared ( Table 2) . As Hemoglobin levels decreased from 11.0 to 10.6 g/dl with infection, we adapted EPO dosage in accordance with the recommendations, to maintain Hemoglobin levels greater than 10 g/dl. Unfortunately we do not have any information about the EPO strategy for hospitalized patients. As shown in table 1, 19 patients treated in outpatient settings had chest CT scan abnormalities. We used the graduation of pulmonary parenchyma lesions described by the Société d'Imagerie Thoracique. 14 Ground glass opacities were the most common radiologic findings on chest CT performed and classified as stage 1 (minimal, 5 pts), stage 2 (moderate, 7 pts), stage 3 (extensive, 5 pts), stage 4 (severe, 1 pt) and stage 5 (critical, 1 pt). As we had many cases of COVID and we wanted to eliminate healthy carriers as The median time from the onset of respiratory symptoms to ICU admission was very short, ranging only from one to two days, and median survival from the onset of symptoms to death was ten days (range four to fifteen days). The duration of hospitalization was ten days (range five to twenty-three days) and the duration in ICU was thirteen days. Besides usual treatments, 84.2 % of patients with COVID-19 received antibiotics: Roxithromycin and Ceftriaxon combination (11 pts), Amoxicillin/Clavulanic Acid combination (7 pts) and others (14 pts). Other measures in treatment of these patients were taken: decrease of the target weight to improve respiratory function, limiting the use of hemodiafiltration, reducing dialysis time in some cases and increasing the dose of anticoagulant. In a single hemodialysis center in Paris, France, we had a high prevalence of COVID-19 among patients. Through extensive efforts, including universal RT-PCR testing of all patients and staff, cohorting patients suspected of having or with COVID-19, and addressing other key logistical issues, including waiting room crowding, we were able to mitigate the effects of COVID, with a minority of cases occurring more than two weeks after the initial patient was diagnosed. Hemodialysis patients with COVID-19 were universally lymphopenic and frequently had abnormal chest imaging. Among hemodialysis patients with COVID-19, mortality was high, at 21%. The logistical issues in HD, such as collective transportation to hemodialysis, waiting room crowding, and the repeated requirement to attend hemodialysis along with the close physical proximity of patients to each other and to staff during hemodialysis, could significantly increase the risk of infection in this setting. Indeed, 10 patients were positive the first week and 13 the second week, representing 60% of the cases, with a dramatic decline after we instituted aggressive mitigation efforts. We were among the first dialysis centers to be affected in Ile de France, with our first case occurring before France's national quarantine measures were in place. The early timing may explain some of the challenges we faced: 3. Universal rt-PCR tests were not easily available in France in the beginning of the epidemic. Our first cases had to be tested in local public hospitals with long wait times for tests and long turnaround times. We were able to manage our own tests in our center and increase systematic patient screening after March 18. Systematic rt-PCR screening led to the identification of positive patients leading to effective isolation. We believe that the addition of chest CT diagnosis with on-demand rt-PCR testing would increase the diagnostic sensibility and decrease the number of "false negative" patients. We also used weekly blood analysis, as unexplained lymphopenia associated with a high CRP level should orient us quickly towards a COVID-19 infection diagnosis. Epidemiological data in patients on maintenance HD during the SARS-CoV-2 outbreak are limited 15 and only several cases have been reported [16] [17] [18] [19] [20] . However, it is important that follow-up was only four days (Feb. 9 to Feb. 13) on Wang's report. 16 The first series of cases came from Wuhan, China. 15 From 14 January 2020 (first confirmed case) to 17 February 2020 (epidemic extinction day), the authors reported that 37 COVID-19 confirmed cases in 230 hemodialysis patients (16.09%). 15 In most patients, COVID-19 symptoms were mild, with no patients admitted to intensive care units. COVID-19 positive dialyzed patients had less lymphopenia than our population, lower serum levels of inflammatory T cells, T helper cells, killer T cells, and NK cells cytokines and milder clinical disease compared to non-hemodialysis patients with COVID-19. During that epidemic, seven patients died including six with COVID-19 and one without COVID-19. The causes of death were apparently not related to pneumonia but due to cardiovascular and cerebrovascular diseases, and hyperkaliemia unlike our deceased patients. The outcome of the four staff members was favorable. 15 Collectively, this study suggests that despite hemodialysis patients being at high risk of being infected with SARS-CoV-2, they are likely to experience mild disease that does not develop into full-blown pneumonia, probably due to the reduced function of the immune system and decreased cytokine storms. 15 Hemoglobin, g/dL (10-12 g/dL) 11.2 (7.9-13.5) 11.0 (7.4-13.5) SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients First cases of coronavirus disease 2019 (COVID-19) in the WHO European www.eurosurveillance.org Region Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China The Novel Coronavirus 2019 epidemic and kidneys China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China Coronavirus COVID-19 has killed more people than SARS and MERS combined, despite lower case fatality rate Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China Hemodialysis and COVID-19: An Achilles' Heel in the Pandemic Health Care Response in the United States Practical indications for the prevention and management of SARS-CoV-2 in ambulatory dialysis patients: lessons from the first phase of the epidemics in Lombardy Mitigating Risk of COVID-19 in Dialysis Facilities Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres On the Frontline of the COVID-19 Outbreak: Keeping Patients on Long-Term Dialysis Safe La société d'Imagerie Thoracique propose un compte-rendu structuré de scanner thoracique pour les patients suspects de COVID-19 Novel Coronavirus Disease in Hemodialysis (HD) Patients: Report from One HD Center in Wuhan COVID-19 in Hemodialysis Patients: A Report of 5 Cases A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease COVID-19 Infection in a Patient with End-Stage Kidney Disease Coronavirus Disease 2019 in a Hemodialysis Patient COVID-19) Pneumonia in a Hemodialysis Patient Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade Management Of Patients On Dialysis And With Kidney Transplant During SARS-COV-2 (COVID-19) Pandemic In Brescia